Why Liver Cancer Screening Needs Better Blood-Based Options?

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, presents an unusual challenge: the disease can develop and progress without obvious symptoms. For people at increased risk, detecting HCC early can make an important difference because more treatment options are available when disease is still localized.

Current surveillance approaches have helped physicians identify liver cancer earlier, but they also have limitations. This has created growing interest in blood-based molecular technologies that may provide additional information about the biological changes associated with cancer.

The Challenge of Detecting HCC Early:

People with cirrhosis, chronic hepatitis B or C, and certain other chronic liver diseases have an increased risk of developing HCC. Surveillance commonly involves liver imaging, sometimes together with measurement of alpha-fetoprotein (AFP) in the blood.

Neither approach is perfect.

Ultrasound performance can be affected by patient and liver characteristics, while AFP may remain within the normal range in many patients who have HCC.

These limitations have created an important need for additional blood-based approaches that can provide different molecular information about the presence of liver cancer.

Looking Beyond Conventional Protein Biomarkers:

AFP is a protein biomarker. Modern molecular diagnostics make it possible to investigate a very different type of signal: cancer-associated RNA circulating in the blood.

One area of research involves fusion transcripts.

Cancer cells can acquire chromosomal rearrangements that join genetic material from two different genes. These rearrangements can create fusion genes, which may produce distinctive RNA molecules called fusion transcripts.

Research underlying MoleculeDx technology has investigated whether selected cancer-associated fusion transcripts can be detected as cell-free RNA in the serum of patients with HCC.

This provides a different way to look at cancer biology: instead of measuring only the concentration of a conventional protein biomarker, molecular testing can look for abnormal RNA signals associated with genetic changes in cancer cells.

Why a Multi-Signal Approach Matters?

Cancer is biologically diverse. A molecular alteration found in one tumor may not be present in every other tumor.

For this reason, relying on a single molecular marker can be limiting.

MoleculeDx has developed a multi-signal approach that evaluates a panel of cancer-associated fusion transcripts rather than depending on one marker alone. The resulting molecular information can then be evaluated computationally as a combined pattern.

This approach forms the basis of Fusion-detect™, the technology underlying the MoleculeDx Liver Cancer Fusion Predictor.

Published research from the scientific program has evaluated combinations of serum fusion-transcript measurements and predictive models in patients with HCC and non-HCC conditions. Performance results from these studies are interpreted in the context of the specific molecular markers, models, specimens and patient cohorts evaluated.

Making Blood-Based Screening Easier to Access:

Scientific performance is only one part of effective screening. A test also needs to be practical for the people who may benefit from it.

MoleculeDx has designed its testing process around a blood sample. Patients can begin the process online and arrange blood collection through available phlebotomy services. The collected sample is then sent to the MoleculeDx CLIA-certified laboratory for molecular analysis.

This approach can make blood-based liver cancer screening more accessible and convenient, particularly for patients who may otherwise need to travel for repeated testing.

A Blood Test Does Not Replace Clinical Evaluation:

Blood-based molecular testing provides information—it does not replace appropriate medical evaluation.

A result indicating cancer-associated molecular signals should be considered together with the patient’s clinical history, risk factors and other findings. When concern for HCC is present, appropriate diagnostic imaging and physician evaluation remain important.

Similarly, no screening test can completely exclude cancer in every patient.

The goal is therefore not to replace physicians or imaging with a blood test. It is to provide another source of biological information that may help identify patients who warrant closer evaluation.

Toward a More Molecular Approach to Liver Cancer Screening:

For decades, liver cancer surveillance has relied largely on imaging and conventional biomarkers such as AFP. Advances in molecular biology now make it possible to examine additional signals associated with the cancer itself.

Cancer-associated fusion transcripts represent one such class of molecular signals.

By combining blood-based detection of multiple fusion transcripts with computational analysis, MoleculeDx is developing a different approach to HCC screening test —one designed to look beyond a single protein biomarker and toward the molecular changes associated with cancer.

For people at increased risk of liver cancer, better blood-based options could ultimately make surveillance more informative, accessible and easier to incorporate into routine care.